-
EBMT Exclusive Interview | Professor Yanmin Zhao: Maintenance Treatment Strategies for FLT3-ITD Mutant AML Patients After Transplantation
FMS-like tyrosine kinase 3 (FLT3) mutations, particularly internal tandem duplication mutations (FLT3-ITD), are one of the significant factors affecting the prognosis of patients with acute myeloid leukemia (AML). Overcoming the challenge of relapse after transplantation in patients with FLT3-mutated AML remains a significant clinical hurdle. At the 50th European Bone Marrow Transplantation (EBMT) annual meeting,…
-
Digital Management of Chronic Progressive Liver Disease in China: Monthly Literature Review (April 2024, Issue 80)
Hello, esteemed experts and colleagues. In this issue of the CDM Monthly Review (Issue 80), we will share six recent articles on the diagnosis and treatment of portal hypertension (four on diagnosis and monitoring, and two on multidisciplinary treatment). We have invited the following experts to review this month’s issue: Dr. Yifei Huang from the…
-
Professor Shichun Lu’s Team: Proportion of Viable Tumor Cells Predicts Prognosis of Targeted Immunotherapy for Liver Cancer
Recently, Professor Shichun Lu’s team from the Chinese PLA General Hospital published an article titled “Application of Proportion of Viable Tumor Cells in Prognosis Evaluation of Initial Unresectable Hepatocellular Carcinoma Patients Undergoing Sequential Surgical Treatment After Conversion Therapy” in the professional journal Chinese Journal of Hepatobiliary Surgery. The study retrospectively analyzed clinical data and pathological…
-
EBMT China’s Voice | Team led by Yi Luo/Yibo Wu: Current Treatment Status and Prognosis of Acute Myeloid Leukemia with t(8;21) Chromosome Translocat
Acute myeloid leukemia (AML) with t(8;21)(q22;q22.1) is one subtype among AML with recurrent genetic abnormalities, characterized by the translocation between chromosome 8q22 and chromosome 21q22. This translocation leads to the fusion of the RUNX1 gene on 8q22 with the RUNX1T1 gene on 21q22, forming the RUNX1-RUNX1T1 fusion gene. From April 14th to 17th, 2024, the…
-
Professor Jun Guo Interprets the Updated CSCO Guidelines on Urothelial Carcinoma and Melanoma | 2024 CSCO Guideline Conference
The 2024 CSCO Guideline Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Hope Science Clinical Oncology Research Foundation, took place in Jinan on April 26-27. At the event, Professor Jun Guo from Peking University Cancer Hospital was interviewed by “Oncology Frontier.” He discussed significant updates in the new editions of…
-
Professor Rui Ge: Review and Outlook on Advances in Breast Cancer Treatment | Northern Breast Cancer Salon Annual Review
As time passes and seasons flow, we always embark on new journeys and endeavors through repeated reviews and outlooks. The annual review of the Northern Breast Cancer Salon and the discussion on the 2024 CSCO BC Guidelines update were held from January 5-6, 2024, in Beijing. “Oncology Frontier” specially interviewed Professor Rui Ge from East…
-
Professor Ying Yuan: Updates to the 2024 CSCO Guidelines for Colorectal Cancer – Enhancing Personalized Treatment from Pathology to Therapy
The 2024 update of the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Colorectal Cancer has been released. The new edition incorporates the latest evidence-based medical developments, adds new biomarkers for colorectal cancer, enriches clinical treatment strategy options, and adjusts the recommendation levels for various treatment protocols. Oncology Frontier interviewed…
Connecting Medical Expertise through Media
